The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Advances in recombinant antibody manufacturing
Open accessAbstract
Since the first use of Chinese hamster ovary (CHO) cells for recombinant protein expression, production processes have steadily improved through numerous advances. In this review, we have highlighted several key milestones that have contributed to the success of CHO cells from the beginning of their use for monoclonal antibody (mAb) expression until today. The main factors influencing the yield of a production process are the time to accumulate a desired amount of biomass, the process duration, and the specific productivity. By comparing maximum cell densities and specific growth rates of various expression systems, we have emphasized the limiting parameters of different cellular systems and comprehensively described scientific approaches and techniques to improve host cell lines. Besides the quantitative evaluation of current systems, the quality-determining properties of a host cell line, namely post-translational modifications, were analyzed and compared to naturally occurring polyclonal immunoglobulin fractions from human plasma. In summary, numerous different expression systems for mAbs are available and also under scientific investigation. However, CHO cells are the most frequently investigated cell lines and remain the workhorse for mAb production until today.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Heterologous protein production using the Pichia pastoris expression system
Macauley‐Patrick, S., Fazenda, M. L., McNeil, B., & Harvey, L. M. (2005) · Yeast · doi:10.1002/yea.1208 · Cited by 1,225
Parekh, R. B., Dwek, R. A., Sutton, B. J., Fernandes, D. L., Leung, A., Stanworth, D., Rademacher, T. W., Mizuochi, T., Taniguchi, T., Matsuta, K., et al. (1985) · Nature · doi:10.1038/316452a0 · Cited by 1,170
Recombinant protein expression in Pichia pastoris
Cregg, J. M., Cereghino, J. L., Shi, J., & Higgins, D. R. (2000) · Molecular Biotechnology · doi:10.1385/mb:16:1:23 · Cited by 927
Glycosylation as a strategy to improve antibody-based therapeutics
Jefferis, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2804 · Cited by 829
Umaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764
Daly, R., & Hearn, M. T. W. (2005) · Journal of Molecular Recognition · doi:10.1002/jmr.687 · Cited by 746
Cell culture processes for monoclonal antibody production
Li, F., Vijayasankaran, N., Shen, A. (., Kiss, R., & Amanullah, A. (2010) · mAbs · doi:10.4161/mabs.2.5.12720 · Cited by 739
Industrialization of mAb production technology: The bioprocessing industry at a crossroads
Kelley, B. (2009) · mAbs · doi:10.4161/mabs.1.5.9448 · Cited by 667
Terminal sugars of Fc glycans influence antibody effector functions of IgGs
Raju, T. S. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.007 · Cited by 521
Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives
Dumont, J., Euwart, D., Mei, B., Estes, S., & Kshirsagar, R. (2016) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2015.1084266 · Cited by 483
Heterogeneity of Monoclonal Antibodies
Liu, H., Gaza-Bulseco, G., Faldu, D., Chumsae, C., & Sun, J. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21180 · Cited by 481
Recombinant protein therapeutics from CHO cells : 20 years and counting
Jayapal, K. P., Wlaschin, K. F., Hu, W., & Yap, M. G. S. (2007) · Chemical engineering progress · Cited by 473
Scallon, B. J., Tam, S. H., McCarthy, S. G., Cai, A. N., & Raju, T. S. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2006.09.005 · Cited by 396
Huang, Y., Hu, W., Rustandi, E., Chang, K., Yusuf‐Makagiansar, H., & Ryll, T. (2010) · Biotechnology Progress · doi:10.1002/btpr.436 · Cited by 350
Ferrara, C., Brünker, P., Suter, T., Moser, S., Püntener, U., & Umaña, P. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.20777 · Cited by 305
In Vivo Deamidation Characterization of Monoclonal Antibody by LC/MS/MS
Huang, L., Lu, J., Wroblewski, V. J., Beals, J. M., & Riggin, R. M. (2005) · Analytical Chemistry · doi:10.1021/ac0494174 · Cited by 266
The secrets of the Bcl-2 family
García-Sáez, A. J. (2012) · Cell Death & Differentiation · doi:10.1038/cdd.2012.105 · Cited by 226
The α1-6-fucosyltransferase gene and its biological significance
Miyoshi, E. (1999) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(99)00166-x · Cited by 221
Differences in the glycosylation of recombinant proteins expressed in HEK and CHO cells
Croset, A., Delafosse, L., Gaudry, J.-P., Arod, C., Glez, L., Losberger, C., Begue, D., Krstanovic, A., Robert, F., Vilbois, F., et al. (2012) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2012.06.038 · Cited by 221
Fan, Y., Jimenez Del Val, I., Müller, C., Wagtberg Sen, J., Rasmussen, S. K., Kontoravdi, C., Weilguny, D., & Andersen, M. R. (2015) · Biotechnology and Bioengineering · doi:10.1002/bit.25450 · Cited by 217
Trummer, E., Fauland, K., Seidinger, S., Schriebl, K., Lattenmayer, C., Kunert, R., Vorauer‐Uhl, K., Weik, R., Borth, N., Katinger, H., et al. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.21013 · Cited by 216
Self-citationQuan, C., Alcala, E., Petkovska, I., Matthews, D., Canova-Davis, E., Taticek, R., & Ma, S. (2008) · Analytical Biochemistry · doi:10.1016/j.ab.2007.09.027 · Cited by 206
Engineering of Pichia pastoris for improved production of antibody fragments
Gasser, B., Maurer, M., Gach, J., Kunert, R., & Mattanovich, D. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.20851 · Cited by 202
Self-citationHumanization of murine monoclonal antibodies through variable domain resurfacing.
Roguska, M. A., Pedersen, J. T., Keddy, C. A., Henry, A. H., Searle, S. J., Lambert, J. M., Goldmacher, V. S., Blättler, W. A., Rees, A. R., & Guild, B. C. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.3.969 · Cited by 201
Jäger, V., Büssow, K., Wagner, A., Weber, S., Hust, M., Frenzel, A., & Schirrmann, T. (2013) · BMC Biotechnology · doi:10.1186/1472-6750-13-52 · Cited by 200
Harris, R. J. (1995) · Journal of Chromatography A · doi:10.1016/0021-9673(94)01255-d · Cited by 197
Borth, N., Mattanovich, D., Kunert, R., & Katinger, H. (2008) · Biotechnology Progress · doi:10.1021/bp0498241 · Cited by 190
Self-citationBenchmarking of commercially available CHO cell culture media for antibody production
Reinhart, D., Damjanovic, L., Kaisermayer, C., & Kunert, R. (2015) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-015-6514-4 · Cited by 183
Self-citationTigges, M., & Fussenegger, M. (2006) · Metabolic Engineering · doi:10.1016/j.ymben.2006.01.006 · Cited by 178
Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies
Satoh, M., Iida, S., & Shitara, K. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.11.1161 · Cited by 175
Damasceno, L. M., Anderson, K. A., Ritter, G., Cregg, J. M., Old, L. J., & Batt, C. A. (2006) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-006-0652-7 · Cited by 163
Ten Years of Orthoclone OKT3 (Muromonab-CD3): A Review
Smith, S. L. (1996) · Journal of Transplant Coordination · doi:10.1177/090591999600600304 · Cited by 163
Optimal conditions for the expression of a single-chain antibody (scFv) gene in Pichia pastoris
Shi, X., Karkut, T., Chamankhah, M., Alting-Mees, M., Hemmingsen, S. M., & Hegedus, D. (2003) · Protein Expression and Purification · doi:10.1016/s1046-5928(02)00706-4 · Cited by 162
Haberger, M., Bomans, K., Diepold, K., Hook, M., Gassner, J., Schlothauer, T., Zwick, A., Spick, C., Kepert, J. F., Hienz, B., et al. (2014) · mAbs · doi:10.4161/mabs.27876 · Cited by 162
High-level expression of recombinant IgG in the human cell line per.c6
Jones, D., Kroos, N., Anema, R., Van Montfort, B., Vooys, A., Kraats, S. V. D., Helm, E. V. D., Smits, S., Schouten, J., Brouwer, K., et al. (2003) · Biotechnology Progress · doi:10.1021/bp025574h · Cited by 158
Clincke, M., Mölleryd, C., Samani, P. K., Lindskog, E. K., Fäldt, E., Walsh, K., & Chotteau, V. (2013) · Biotechnology Progress · doi:10.1002/btpr.1703 · Cited by 152
Structural changes of immunoglobulin G oligosaccharides with age in healthy human serum
Yamada, E., Tsukamoto, Y., Sasaki, R., Yagyu, K., & Takahashi, N. (1997) · Glycoconjugate Journal · doi:10.1023/a:1018582930906 · Cited by 151
Chen, G., Wang, Y., Qiu, L., Qin, X., Liu, H., Wang, X., Wang, Y., Song, G., Li, F., Guo, Y., et al. (2012) · Journal of Proteomics · doi:10.1016/j.jprot.2012.02.001 · Cited by 150
Altamirano, C., Paredes, C. J., Illanes, A., Cairó, J. J., & Gòdia, F. (2004) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2004.02.004 · Cited by 148
Haverick, M. A., Mengisen, S., Shameem, M., & Ambrogelly, A. (2014) · mAbs · doi:10.4161/mabs.28693 · Cited by 144
Zahn‐Zabal, M., Kobr, M., Girod, P., Imhof, M. O., Chatellard, P., de Jesus, M., Wurm, F. M., & Mermod, N. (2001) · Journal of Biotechnology · doi:10.1016/s0168-1656(00)00423-5 · Cited by 144
CHO cell engineering to prevent polypeptide aggregation and improve therapeutic protein secretion
Le Fourn, V., Girod, P.-A., Buceta, M., Regamey, A., & Mermod, N. (2014) · Metabolic Engineering · doi:10.1016/j.ymben.2012.12.003 · Cited by 144
Telikepalli, S. N., Kumru, O. S., Kalonia, C. K., Esfandiary, R., Joshi, S. B., Middaugh, C. R., & Volkin, D. B. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23839 · Cited by 137
Jones, A. J. S., Papac, D. I., Chin, E. H., Keck, R. G., Baughman, S. A., Lin, Y. S., Kneer, J., & Battersby, J. E. (2007) · Glycobiology · doi:10.1093/glycob/cwm017 · Cited by 137
Altamirano, C., Illanes, A., Casablancas, A., Gámez, X., Cairó, J. J., & Godia, C. (2001) · Biotechnology Progress · doi:10.1021/bp0100981 · Cited by 130
Improved recombinant gene expression in CHO cells using matrix attachment regions
Kim, S., Kim, J.-S., Park, D.-H., Kang, H. S., Yoon, J., Baek, K., & Yoon, Y. (2003) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2003.09.015 · Cited by 129
Assessing monoclonal antibody product quality attribute criticality through clinical studies
Goetze, A. M., Schenauer, M. R., & Flynn, G. C. (2010) · mAbs · doi:10.4161/mabs.2.5.12897 · Cited by 105
Effect of PDI Overexpression on Recombinant Protein Secretion in CHO Cells
Davis, R., Schooley, K., Rasmussen, B., Thomas, J., & Reddy, P. (2000) · Biotechnology Progress · doi:10.1021/bp000107q · Cited by 105
Use of the chicken lysozyme 5′ matrix attachment region to generate high producer CHO cell lines
Girod, P., Zahn‐Zabal, M., & Mermod, N. (2005) · Biotechnology and Bioengineering · doi:10.1002/bit.20563 · Cited by 105
Gurramkonda, C., Adnan, A., Gäbel, T., Lünsdorf, H., Roß, A., Nemani, S. K., Swaminathan, S., Khanna, N., & Rinas, U. (2009) · Microbial Cell Factories · doi:10.1186/1475-2859-8-13 · Cited by 99
Benton, T., Chen, T., McEntee, M., Fox, B., King, D., Crombie, R., Thomas, T. C., & Bebbington, C. (2002) · Cytotechnology · doi:10.1023/a:1021141712344 · Cited by 98
Li, B., Ryan, P. W., Ray, B. H., Leister, K. J., Sirimuthu, N. M. S., & Ryder, A. G. (2010) · Biotechnology and Bioengineering · doi:10.1002/bit.22813 · Cited by 95
Chung, J. Y., Lim, S. W., Hong, Y. J., Hwang, S. O., & Lee, G. M. (2004) · Biotechnology and Bioengineering · doi:10.1002/bit.10919 · Cited by 88
Maccani, A., Landes, N., Stadlmayr, G., Maresch, D., Leitner, C., Maurer, M., Gasser, B., Ernst, W., Kunert, R., & Mattanovich, D. (2014) · Biotechnology Journal · doi:10.1002/biot.201300305 · Cited by 87
Self-citationTrummer, E., Fauland, K., Seidinger, S., Schriebl, K., Lattenmayer, C., Kunert, R., Vorauer‐Uhl, K., Weik, R., Borth, N., Katinger, H. W. D., et al. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.20958 · Cited by 81
Self-citationZeiser, A., B�dard, C., Voyer, R., Jardin, B. A., Tom, R., & Kamen, A. (1999) · Biotechnology and Bioengineering · doi:10.1002/(sici)1097-0290(19990405)63:1<122::aid-bit13>3.0.co;2-i · Cited by 79
Downey, B. J., Graham, L. J., Breit, J. F., & Glutting, N. K. (2013) · Biotechnology Progress · doi:10.1002/btpr.1845 · Cited by 78
Brorson, K., & Jia, A. (2014) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2014.06.012 · Cited by 63
Cregg, J. M. (2007) · Methods in molecular biology · doi:10.1007/978-1-59745-456-8_1 · Cited by 56
Mohan, C., & Lee, G. M. (2010) · Biotechnology and Bioengineering · doi:10.1002/bit.22781 · Cited by 56
Comparison of Surface Accessible Residues in Human and Murine Immunoglobulin Fv Domains
Pedersen, J. T., Henry, A. H., Searle, S. J., et al. (1994) · Journal of Molecular Biology · doi:10.1006/jmbi.1994.1050 · Cited by 55
Heterologous protein production using euchromatin-containing expression vectors in mammalian cells
Zboray, K., Sommeregger, W., Bogner, E., Gili, A., Sterovsky, T., Fauland, K., Grabner, B., Stiedl, P., Moll, H. P., Bauer, A., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv475 · Cited by 52
Self-citationStansfield, S. H., Allen, E. E., Dinnis, D. M., Racher, A. J., Birch, J. R., & James, D. C. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.21263 · Cited by 49
Direct analysis of mAb aggregates in mammalian cell culture supernatant
Paul, A. J., Schwab, K., & Hesse, F. (2014) · BMC Biotechnology · doi:10.1186/s12896-014-0099-3 · Cited by 47
Diversity in structure and functions of antibody sialylation in the Fc
Raju, T. S., & Lang, S. E. (2014) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2014.06.014 · Cited by 46
IgG-Fc N-glycosylation at Asn297 and IgA O-glycosylation in the hinge region in health and disease
Xue, J., Zhu, L.-P., & Wei, Q. (2013) · Glycoconjugate Journal · doi:10.1007/s10719-013-9481-y · Cited by 43
Over-expression of hTERT in CHO K1 results in decreased apoptosis and reduced serum dependency
Crea, F., Sarti, D., Falciani, F., & Al‐Rubeai, M. (2005) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2005.07.021 · Cited by 42
Clincke, M., Mölleryd, C., Zhang, Y., et al. (2011) · BMC Proceedings · doi:10.1186/1753-6561-5-s8-p105 · Cited by 41
Defined protein and animal component-free NS0 fed-batch culture
Spens, E., & Häggström, L. (2007) · Biotechnology and Bioengineering · doi:10.1002/bit.21509 · Cited by 41
Generation of stable cell clones expressing mixtures of human antibodies
de Kruif, J., Kramer, A., Nijhuis, R., der Zande, V. Z.-V., den Blanken-Smit, R., Clements, C., Visser, T., Keehnen, R., den Hartog, M., Throsby, M., et al. (2010) · Biotechnology and Bioengineering · doi:10.1002/bit.22763 · Cited by 38
Kishishita, S., Nishikawa, T., Shinoda, Y., Nagashima, H., Okamoto, H., Takuma, S., & Aoyagi, H. (2014) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2014.10.028 · Cited by 35
Glycan variability on a recombinant IgG antibody transiently produced in HEK-293E cells
Nallet, S., Fornelli, L., Schmitt, S., Parra, J., Baldi, L., Tsybin, Y. O., & Wurm, F. M. (2012) · New Biotechnology · doi:10.1016/j.nbt.2012.02.003 · Cited by 34
Microchip Zone Electrophoresis for High-Throughput Analysis of Monoclonal Antibody Charge Variants
Wheeler, T. D., Sun, J., Pleiner, S., Geier, H., Dobberthien, P., Studts, J., Singh, R., & Fathollahi, B. (2014) · Analytical Chemistry · doi:10.1021/ac500497n · Cited by 34
Hyperosmolarity enhances transient recombinant protein yield in Chinese hamster ovary cells
Zhang, X., García, I. F., Baldi, L., Hacker, D. L., & Wurm, F. M. (2010) · Biotechnology Letters · doi:10.1007/s10529-010-0331-8 · Cited by 32
Lee, J. C., Chang, H. N., & Oh, D. J. (2005) · Biotechnology Progress · doi:10.1021/bp0497942 · Cited by 28
Chemical Caspase Inhibitors Enhance Cell Culture Viabilities and Protein Titer
Arden, N., Ahn, S., Vaz, W., Rhodes, M., Hancock, C., Abitorabi, M. A., & Betenbaugh, M. J. (2007) · Biotechnology Progress · doi:10.1021/bp060222m · Cited by 27
Kunert, R., & Casanova, E. (2013) · Bioengineered · doi:10.4161/bioe.24060 · Cited by 21
Self-citationHo, Y. S., Kiparissides, A., Pistikopoulos, E. N., & Mantalaris, A. (2011) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2011.08.022 · Cited by 17
Cited by
Considerations for the Design of Antibody-Based Therapeutics
Goulet, D. R., & Atkins, W. M. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.05.031 · Cited by 302
mRNA Delivery for Therapeutic Anti-HER2 Antibody Expression In Vivo
Rybakova, Y., Kowalski, P. S., Huang, Y., Gonzalez, J. T., Heartlein, M. W., DeRosa, F., Delcassian, D., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.05.012 · Cited by 218
Fisher, A. C., Kamga, M.-H., Agarabi, C., Brorson, K., Lee, S. L., & Yoon, S. (2019) · Trends in Biotechnology · doi:10.1016/j.tibtech.2018.08.008 · Cited by 180
Animal immunization, in vitro display technologies, and machine learning for antibody discovery
Laustsen, A. H., Greiff, V., Karatt-Vellatt, A., Muyldermans, S., & Jenkins, T. P. (2021) · Trends in Biotechnology · doi:10.1016/j.tibtech.2021.03.003 · Cited by 147
Amann, T., Schmieder, V., Faustrup Kildegaard, H., Borth, N., & Andersen, M. R. (2019) · Biotechnology and Bioengineering · doi:10.1002/bit.27101 · Cited by 46
Metadata
- Authors
- Kunert, R., & Reinhart, D.
- Venue
- Applied Microbiology and Biotechnology
- Published
- 2016-03-03
- Volume
- 100
- Issue
- 8
- Pages
- 3451-3461
- ISSN
- 0175-7598 (ISSN-L)
- 1432-0614
- OpenAlex
- W2289965054
- Cited by
- 417
- References
- 79
- FWCI
- 20.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.